Tumor-associated carbohydrate antigen GM2 (GM2)

Tumor-associated carbohydrate antigen GM2 (GM2 ganglioside) is a glycosphingolipid composed of a ceramide backbone linked to an oligosaccharide that includes a terminal sialic acid[2][4][10]. GM2 is abundantly expressed on the surface of certain cancer cells, notably melanoma, sarcoma, and several epithelial cancers, where it acts as a target for immunotherapeutic monoclonal antibodies and cancer vaccines[1][7][3]. Its overexpression in tumors leverages altered glycosylation characteristic of cancer cells, facilitating immune evasion and promoting malignant behaviors[3]. Defects in GM2 catabolism, typically due to inherited enzyme deficiencies (e.g., HEXA, HEXB, GM2A), result in lysosomal storage disorders such as Tay-Sachs and Sandhoff diseases[4][10]. GM2-targeted therapies aim to induce GM2-specific antibody responses that mediate tumor cell destruction, and ongoing vaccine and antibody engineering aim to overcome its relatively weak immunogenicity in humans[1][7][3].

Other names

Ganglioside GM2G(M2) gangliosideGM2 antigenTACA GM2

Induction of anti-GM2 antibody immune responses (ADCC, complement-mediated cytotoxicity), Cancer vaccine/adjuvant therapy promoting immune recognition